Your source for all Prime Therapeutics' May 2025 Drug Insights publications.

Prime Therapeutics (Prime) provides you with regular updates on the drug pipeline as well as next-generation clinical information and hot topics. The following Drug Insights publications for May 2025 will keep you informed on what’s trending now.

---

Released May 14, 2025

Watch List

A monthly report of the most notable drugs that may significantly affect the populations we serve. Drug highlights this month are brensocatib / Insmed,  rebisufligene etisparvovec / Ultragenyx, semaglutide (Wegovy) / Novo Nordisk and more.

Oncology Insights

Featuring commentary by Abby Kim, PharmD, BCOP, on developments in the oncology space, this installment features breakthroughs in liquid biopsy testing to help detect cancer at an early stage. 

---

Released May 15, 2025

High-Cost Therapy Profile

Providing a clinical deep dive into a select high-cost drug in the pipeline, this month’s profile features Vusolimogene oderparepvec (RP1), an immunotherapy targeting advanced melanoma. 

---

Released May 21, 2025

FDA Decisions Expected for June 2025

A breakdown of FDA decisions expected of new drugs anticipated to hit the market, this edition covers ranibizumab, garadacimab and more. 

---

Released May 27, 2025

GLP-1 Pipeline Update: May 2025

The latest edition of our quarterly GLP-1 publication offers insights into the evolving GLP-1 pipeline and anticipated indications. Explore what’s new in the latest issue. 

---

Released June 4, 2025

NEW! Trending Topics & Drug Approvals: May 2025 

We've combined Clinical Highlights and Drug Approvals into this new, monthly publication, which covers the latest specialty and traditional drug approvals. This inaugural edition features the FDA's clearance of the first blood test to aid in diagnosing Alzheimer's disease.

---

Looking for previous 2025 drug insights publications?

Simply click on the month to access past editions of our drug insights.

April 2025

March 2025

February 2025

January 2025

 

All brand names are property of their respective owners.